ClinicalTrials.gg
Active, not recruitingNCT06144645VNS4PWSUpdated Apr 6, 2026

A Clinical Evaluation of Non-Invasive Vagus Nerve Stimulation for Temper Outbursts in People With PWS

A Phase 3 interventional study of tVNS, intermittent stimulation and tVNS, continuous stimulation in Prader-Willi Syndrome, sponsored by Foundation for Prader-Willi Research. Active, not recruiting at 18 sites in United States. Open to participants aged 10 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-04-06.

Sponsored by Foundation for Prader-Willi Research · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
10 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Prader-Willi Syndrome with a site in United States — 9 open to participants now, 14 under way, 3 of them phase 3. Prader-Willi Syndrome · United States.

Planned enrollment
14th of 58
102 · median 23
Started
2024
with 5 others
Phase 3
14 of 69
2 open now
Primary completion
2027-04
later than 5 of 13 live
Registered
57th of 69
by date

Among the 69 studies in Prader-Willi Syndrome with a site in United States, this one is the 14th largest by planned enrollment of the 58 interventional ones that give a count, is one of 6 that started in 2024, is one of 14 in phase 3, reaches primary completion later than 5 of the 13 other live ones, and was the 57th registered.

Prader-Willi Syndrome

144 studies on the registry are indexed under Prader-Willi Syndrome; 23 are open to participants now.

Browse Prader-Willi Syndrome studies →

Open to participants now

9 of the 69 studies in Prader-Willi Syndrome with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 16 Prader-Willi Syndrome studies recruiting now, 7 (44%) set no upper age limit and 9 (56%) stop at 75 or younger; 11 take children under 18; 1 takes healthy volunteers.

This study: 10 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Prader-Willi Syndrome with a site in United States, or all of them as a file.
02

Study summary

The goal of the VNS4PWS clinical study is to test the efficacy, safety, and acceptability of transcutaneous vagus nerve stimulation (tVNS) treatment in people with PWS.

Read the detailed description

The main questions the VNS4PWS study seeks to answer are: (1) is tVNS treatment safe in people with PWS, (2) is tVNS treatment acceptable to people with PWS, and (3) is tVNS an effective treatment to reduce temper outbursts in people with PWS. Participants will wear the tVNS device daily for 4 hours over a period of 9 months. Two different doses of tVNS will be compared. During the final three months of the trial, the effect of stopping treatment will be studied. After the first year of the study, participants will have the opportunity to continue on to a 1-year open label extension period during which active tVNS treatment will be resumed.

03

Conditions studied

  • Prader-Willi Syndrome

Browse trials for

Keywords

  • Prader-Willi syndrome
  • PWS
  • Prader
04

Who can participate

Ages eligible
10 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Genetically proven diagnosis of PWS.
  2. Age 10-40 years.
  3. History in the last six months of an average of at least two temper outbursts per week.
  4. Able to comply with requirements of study and provide consent or assent; If consent is to be provided by the participant's guardian, same applies to the guardian.
  5. Concomitant use of psychiatric medication is allowed; participant must be on a stable dose 90 days prior to screening with no plans for dose modification during the course of the study.
  6. Concomitant use of psychotherapy/counseling is allowed. Therapies for mental health or behavior challenges, including applied behavior analysis (ABA) are also allowed; however, participant must be on a stable regimen 90 days prior to screening with no plans for modification during the course of the study.
  7. Living with family or in another setting with family members or staff willing to support the participant and the required data collection.
  8. Agree to share tVNS patient application compliance and daily temper outburst data with the sponsor.
  9. Access to cellular data or Wi-Fi.
  10. Participant and caregiver speak American English as first language or are fluent in American English.

Exclusion criteria

Exclusion Criteria:

  1. Positive pregnancy test at screening, baseline, or at any point in the study.
  2. Evidence of active or recent unstable serious mental illness, including, psychosis, mania, severe depression, or suicidality.
  3. Moved to present residential placement in last three months or less.
  4. Likely move in residential placement during the course of the study.
  5. Cardiac abnormalities including medically documented history of cardiac disease or cardiac arrhythmia, documented resting heart rate ≤ 50 beats per minute (BPM); or history of 2° type 2 or 3° heart block on (ECG).
  6. Evidence of abnormalities of blood, liver, or kidney function from clinical safety laboratory assessments as determined by the Site Investigator.
  7. History of blood clot, pulmonary embolism, or deep vein thrombosis.
  8. Prior diagnosis of epilepsy or currently active seizures.
  9. Current enrollment in the active phase of different clinical trial or interventional study.
  10. Current use of hearing aids or implantable medical devices including implanted vagus nerve stimulation (iVNS) device, implanted cardiac pacemaker, implanted cardiac defibrillator, cochlear implants, cerebral shunt or cardiac implantable electrical devices.
  11. Presence of dermal abnormalities at the stimulation site that would interfere with the ability of the tVNS device to function properly.
  12. Presence of an allergy to titanium, titanium-iridium, thermoplastic elastomers, perfluoroethylene propylene, or polyurethane elastomers, or components of / preservatives present in the device electrode cream (Ceteareth-20, Propylene Glycol, Bentonite, Polysorbate 20, Phenoxyethanol, Ethylhexylglycerin).
  13. Severe, untreated sleep apnea, as self-reported by subject or caregiver or suspected by Site Investigator.
  14. Subject is, in the opinion of the Investigator, not suitable to participate in the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
102 participants (estimated)

Study arms

  • Active comparator
    tVNS, Intermittent Stimulation

    28 seconds on, 32 seconds off

    Device: tVNS, intermittent stimulation

  • Active comparator
    tVNS, Continuous Stimulation

    continuous stimulation

    Device: tVNS, continuous stimulation

Interventions

  • DevicetVNS, intermittent stimulation

    transcutaneous vagus nerve stimulation, intermittent stimulation

    Also known as: tVNS R, manufactured by tVNS Technologies, intermittent stimulation

  • DevicetVNS, continuous stimulation

    transcutaneous vagus nerve stimulation, continuous stimulation

    Also known as: tVNS R, manufactured by tVNS Technologies, continuous stimulation

06

What researchers measure

Primary outcomes

  1. To determine the safety profile and tolerability of tVNS in PWS, as assessed by the frequency, severity, and seriousness of adverse events determined during the study.

    Frequency, severity, and seriousness of adverse events during the study.

    Time frame: Through study completion, an average of 1 year

  2. To determine the acceptability profile of tVNS in PWS as assessed by the rate of withdrawal from the study.

    The acceptability profile of tVNS in PWS will be measured by the rate of withdrawal from the study.

    Time frame: Through study completion, an average of 1 year

  3. To determine the acceptability profile of tVNS in PWS as assessed by the rates of device use compliance during the study.

    The acceptability profile of tVNS in PWS will be measured by the rates of device use compliance throughout the study.

    Time frame: Through study completion, an average of 1 year

  4. To determine the efficacy of tVNS in reducing temper outbursts in people with PWS aged 10 - 40 years.

    Change in Aberrant Behavior Checklist, irritability subscale. A lower score indicates a better outcome whereas a higher score indicates a worse outcome. The minimum score is zero and the maximum score is 45.

    Time frame: Baseline to month 9

Secondary outcomes

  1. To determine the efficacy of tVNS in reducing temper outbursts in people with PWS aged 10 - 40 years over the course of the study as assessed by the irritability subscale of the Aberrant Behavior Checklist.

    Aberrant Behavior Checklist irritability subscale. A lower score indicates a better outcome whereas a higher score indicates a worse outcome. The minimum score is zero and the maximum score is 45.

    Time frame: Baseline to months 3, 6, 9.

  2. To determine whether tVNS reduces the average number of temper outbursts per day, as assessed by the Daily Survey.

    The Daily Survey will collect caregiver-reported data on the number of temper outbursts per day. A lower score indicates a better outcome and a higher score indicates a worse outcome. The minimum daily score is zero and the maximum daily score that the scale can capture is 20.

    Time frame: Baseline to months 3, 6, 9, and 12.

  3. To determine whether tVNS reduces the average intensity of daily temper outbursts as measured by the Daily Survey.

    The Daily Survey will collect caregiver-reported data on the intensity of daily temper outbursts. A higher score indicates a worse outcome and a lower score indicates a better outcome. The minimum score is 1 and the maximum score is 7.

    Time frame: Baseline to months 3, 6, 9, and 12.

  4. To determine whether tVNS reduces the average duration of temper outbursts per day.

    The Daily Survey will collect caregiver-reported data on the duration of daily temper outbursts. The minimum score is 1 and the maximum score is 7.

    Time frame: Baseline to months 3, 6, 9, and 12.

  5. To determine whether tVNS decreases PWS-associated hyperphagic behaviors as measured by the Hyperphagia Questionnaire for Clinical Trials.

    Stimulation of the vagus nerve may impact hyperphagic drive. It may also impact eating behaviors and the ability of the person with PWS to cope with eating restrictions. Higher scores indicate a worse outcome and lower scores indicate a better outcome. The minimum score is 0 and the maximum score is 36.

    Time frame: Baseline to months 3, 6, and 9.

  6. To determine whether tVNS treatment decreases skin picking in PWS, as assessed by the Self Injury Trauma Scale.

    The Self Injury Trauma Scale is a widely used method for quantifying surface tissue damage caused by self-injurious behavior. A lower score indicates a better outcome and a higher score indicates a worse outcome. The minimum score is 1 and the maximum is 5.

    Time frame: Baseline to months 3, 6, and 9.

  7. To determine whether tVNS decreases anxiousness and distress in PWS as measured by the PWS Anxiousness and Distress Questionnaire.

    tVNS may impact behaviors associated with anxiousness and distress, which are common in PWS. A lower score indicates a better outcome and a higher score indicates a worse outcome. The minimum score is 0 and the maximum is 56.

    Time frame: Change in PWS Anxiousness and Distress Questionnaire at baseline and months 3, 6, and 9.

  8. To determine whether reductions in temper outbursts result in reduced caregiver burden as measured by the Zarit Burden Interview.

    Reduction in outbursts is expected to positively impact other members of the participant's family - this measure may reflect improvements in family relationships. A higher score indicates a worse outcome. A lower score indicates a better outcome. The minimum score is 0 and the maximum score is 88.

    Time frame: Change in Zarit Burden Interview (ZBI) between baseline and month 9.

  9. To determine whether reductions in temper outburst is associated with improved quality of life as measured by the Parent Proxy Global Health 7.

    Reduction in outbursts is expected to meaningfully improve quality of life as assessed by the Parent Proxy Global Health 7. A higher score indicates a better outcome and a lower score indicates a worse outcome. The minimum score is 7. The maximum score is 35.

    Time frame: Change in Parent Proxy Global Health 7 from baseline to months 3, 6, 9.

  10. To assess whether overall disease severity is improved as measured by the Change in the Clinical Global Impression of disease severity.

    This measure will serve as an anchor to assess the meaningfulness of reductions in temper outbursts. A lower score indicates a better outcome. A higher score indicates a worse outcome. The maximum score is 7. The minimum score is 1.

    Time frame: Change in the Clinical Global Impression of disease severity at baseline and months 3, 6, 9.

  11. To assess whether there is a global improvement in behavior as assessed by the Clinical Global Impression of Improvement.

    Global changes in behavior and will serve as an anchor to assess the meaningfulness of change. A lower score indicates a better outcome. A higher score indicates a worse outcome. The maximum score is 7. The minimum score is 1.

    Time frame: Change in the Clinical Global Impression of Improvement from baseline to months 3, 6, 9.

Other outcomes

  1. Informant and self-reported measures of acceptability as assessed by a qualitative exit interview.

    To qualitatively determine the acceptability of tVNS in people with PWS and to better understand specific reasons for discontinuation that occurred in this study.

    Time frame: Through study completion, an average of 1 year.

  2. Identification of responder characteristics as identified in a qualitative exit interview.

    Participant characteristics and information provided in semi-structured exit interviews will inform efforts to identify those most likely to benefit from this intervention.

    Time frame: Through study completion, an average of 1 year.

  3. To assess the change heart rate variability (HRV) in a subset of participants.

    Heart rate variability is abnormal in PWS, and VNS may cause changes in HRV.

    Time frame: Through study completion, an average of 1 year.

07

Study locations

18 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2024 (actual). Primary completion is estimated for Apr 2027, 38 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2023
First posted
Nov 22, 2023
StartActual
Jan 8, 2024
Primary completionEst.
Apr 1, 2027
CompletionEst.
Apr 1, 2027
Last update
Apr 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06144645
Lead sponsor
Foundation for Prader-Willi Research
Collaborators
RTI International
Responsible party
Sponsor
First posted
Nov 22, 2023
Start date
Jan 8, 2024
Primary completion
Apr 1, 2027 (estimated)
Completion
Apr 1, 2027 (estimated)
Last update
Apr 6, 2026

Study contacts

Theresa Strong, PhD
principal investigator · Foundation for Prader-Willi Research
Deepan Singh, MD
principal investigator · Maimonides Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion